NFIL3 overexpression in the liver promotes gluconeogenesis, disrupts lipid metabolism and insulin signalling, induces insulin resistance in the liver and muscles, and increases the risk of metabolic syndrome (Matsumura et al., 2021). Here, NFIL3 is linked to metabolic syndrome.